Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$1.89 USD
+0.11 (6.18%)
Updated Apr 22, 2024 11:49 AM ET
After-Market: $1.75 -0.14 (-7.41%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 3 |
Average Target Price | $16.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | -5.92 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.67 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/2/2024 | Roth Capital Partners | Jonathan Aschoff | Strong Buy | Strong Buy |
12/19/2023 | Brookline Capital Markets | Kemp Dolliver | Hold | Hold |
12/1/2023 | LadenburgThalmann | Ahu Demir | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.